ArticleMMWR. Morbidity and mortality weekly report2017
Malignant Mesothelioma Mortality - United States, 1999-2015.
Article in MMWR. Morbidity and mortality weekly report, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03918252 (Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma), which is not on this map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.Journal for immunotherapy of cancer · 2022Guideline
- Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.International journal of environmental research and public health · 2020Pooled it
- Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis.Environmental health : a global access science source · 2018Pooled it
- Retrospective cohort study on prognostic factors of malignant pleural effusion secondary to pleural mesothelioma.Journal of thoracic disease · 2026Article
- Burden of cancer attributable to occupational asbestos exposure in the Americas, 1990-2023: an analysis using the Global Burden of Disease Study 2023.Lancet regional health. Americas · 2026Article
- Malignant mesothelioma of the tunica vaginalis testis: A case report.Oncology letters · 2026Article
- Review
- Malignant mesothelioma of the tunica vaginalis testis initially misdiagnosed as a benign testicular hydrocele: a case report.Frontiers in oncology · 2026Article
- The genetics of cancer heterogeneity and mesothelioma.Frontiers in oncology · 2026Review
- The Role of Breath Analysis in the Non-Invasive Early Diagnosis of Malignant Pleural Mesothelioma (MPM) and the Management of At-Risk Individuals.Molecules (Basel, Switzerland) · 2025Observational
- Neoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report.Immunotherapy · 2025Article
- A novel mesothelioma molecular classification based on malignant cell differentiation.Cancer cell international · 2025Article
- Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.JTO clinical and research reports · 2025Article
- Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study.Medicina (Kaunas, Lithuania) · 2025Article
- Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors.Journal of the American Chemical Society · 2025Article
- External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.Frontiers in oncology · 2025Article
- An evaluation of trends for mesothelioma mortality in American women: Addressing the content of a recent Morbidity and Mortality Weekly Report (MMWR).Toxicology and industrial health · 2025Review
- Trends and Projections of Mortality Attributed to Occupational Neoplasms and Occupational Tracheal, Bronchus, and Lung Cancer in the World, G7 Countries and Turkey.Iranian journal of public health · 2024Article
- Ship recycling process in Bangladesh and a survey-based risk assessment with mitigation proposal.Heliyon · 2024Article
- Asbestos ban policies and mesothelioma mortality in Greece.BMC public health · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesothelioma is a neoplasm associated with occupational and environmental inhalation exposure to asbestos* fibers and other elongate mineral particles (EMPs) (1-3). Patients have a median survival of approximately 1 year from the time of diagnosis (1). The latency period from first causative exposure to malignant mesothelioma development typically ranges from 20 to 40 years but can be as long as 71 years (2,3). Hazardous occupational exposures to asbestos fibers and other EMPs have occurred in a variety of industrial operations, including mining and milling, manufacturing, shipbuilding and repair, and construction (3). Current exposures to commercial asbestos in the United States occur predominantly during maintenance operations and remediation of older buildings containing asbestos (3,4). To update information on malignant mesothelioma mortality (5), CDC analyzed annual multiple cause-of-death records
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.